Navigation Links
Arena Pharmaceuticals Announces Public Offering of Common Stock
Date:7/7/2009

SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on November 25, 2008, which became effective on December 3, 2008. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by telephone at 800.747.3924.

    Contact:  Jack Lief
              President and CEO

              Robert E. Hoffman
              VP, Finance and CFO
              Arena Pharmaceuticals, Inc.
              858.453.7200, ext. 222

www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
3. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
4. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
5. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
8. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
11. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and well-known ... to offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon ... Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud to ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. ... of directors: Christopher Gabrieli ... serve as chairman of the board of Akcea Therapeutics. ... of Forest Laboratories. Sandford D. Smith ... "We are excited to announce this expansion to ...
(Date:3/28/2017)... , March 28, 2017 ... expected to reach a value of USD 4.5 billion ... View Research, Inc. Proper closure of injured tissues post ... and function. Postoperative leakages occur in 3% to 15% ... They are responsible for one third of postoperative deaths ...
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
Breaking Medicine Technology: